Your Article Summary
Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer
Cancer Chemotherapy and Pharmacology, 06/30/09
Park I et al. - The pharmacokinetics of S-1 was not influenced by oxaliplatin. S-1/Oxaliplatin combination therapy is highly active against AGC and has a favorable toxicity profile.
Related Articles
CHD5 is down-regulated through promoter hypermethylation in gastric cancer
BMC: Journal of Biomedical Science, 10/26/09
Relevance Score: 71%
Promoter hypermethylation mediates downregulation of thiamine receptor slc19a3 in gastric cancer
Tumor Biology, 10/12/09
Relevance Score: 71%
KAP1 Is Associated With Peritoneal Carcinomatosis in Gastric Cancer
Annals of Surgical Oncology, 11/11/09
Relevance Score: 69%
Management of patients with pregnancy-associated gastric cancer in Japan: a mini-review
International Journal of Clinical Oncology, 10/30/09
Relevance Score: 69%
A Study of Oxidative Stress Parameters in Anti-Helicobacter Pylorus Immunoglobulin G Positive and Negative Gastric Cancer Patients
Yonsei Medical Journal, 10/29/09
Relevance Score: 69%
Today in GI Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Factors associated with psychological distress and grief resolution in surviving spouses of patients with advanced gastrointestinal cancer
Supportive Care in Cancer, 12/01/09
Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer
Carcinogenesis, 12/01/09
Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins
Blood, 12/01/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole
Breast Cancer Research and Treatment, 12/02/09
A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action
Breast Cancer Research and Treatment, 12/02/09
FDA Drug Approval Summary: Bevacizumab (Avastin) as Treatment of Recurrent Glioblastoma Multiforme
The Oncologist, 12/02/09

See Latest Articles